Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study.

Autor: Kadono, Yoshifumi1 (AUTHOR) yskadono@yahoo.co.jp, Konaka, Hiroyuki1,2 (AUTHOR), Nohara, Takahiro1 (AUTHOR), Izumi, Kouji1 (AUTHOR), Anai, Satoshi3 (AUTHOR), Fujimoto, Kiyohide3 (AUTHOR), Koguchi, Tomoyuki4 (AUTHOR), Ishibashi, Kei4,5 (AUTHOR), Kawai, Noriyasu6 (AUTHOR), Nakane, Keita7 (AUTHOR), Iba, Akinori8 (AUTHOR), Masumori, Naoya9 (AUTHOR), Takahara, Shizuko10 (AUTHOR), Mizokami, Atsushi1 (AUTHOR)
Zdroj: Cancers. May2023, Vol. 15 Issue 10, p2745. 15p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje